-
Four challenges and countermeasures for CAR-T treatment of solid tumors
Time of Update: 2021-11-14
Reduce immunosuppression in TME (Source: American Journal of Cancer Research) At the same time, since TGFβ is an important immunosuppressive pathway, blocking TGFβ signaling can also improve the anti-tumor effect of CAR-T .
-
The world's first subcutaneous injection and the first domestically produced PD-L1 will be approved soon!
Time of Update: 2021-11-14
》The price of cabbage reappeared in China Times' "Magical Tumor Drug": Yuheng Bio-PD-1 is 3,300 yuan a piece, or the new round of medical insurance negotiations will reduce the annual cost to 30,000-40,000 yuan?
-
Changes and trends in the global drug R&D pipeline in 2021
Time of Update: 2021-11-14
▲The number of drugs in the global drug R&D pipeline from 2001 to 2021 (picture source: reference [1]) However, the analysis of drug data classified according to the research and development stage can reveal the impact of the new crown epidemic.
-
Thinking: How to carry out market access for pharmaceutical companies under the new situation?
Time of Update: 2021-11-14
In the context of an era where the long-term economic growth rate is declining due to the epidemic, the aging of the population is intensified, the level of medical security needs to be improved, and the price adjustment of medical services needs to create space, the gold content of market access is increasing, and at the same time, we want to be in the pharmaceutical industry at a high speed.
-
National talks about drug equipment: no less than 30% for tertiary hospitals, and no less than 20% for tertiary and tertiary Chinese hospitals!
Time of Update: 2021-11-14
It is required to implement classified management of nationally negotiated drugs to improve the level of supply security; select "dual-channel" management designated retail pharmacies to form a security joint force with medical institutions; improve payment policies and determine the level of adaptive security .
-
Source innovation and payment problems to be solved How can medical innovation make patients “usable” and “affordable”?
Time of Update: 2021-11-14
◎Conway, Executive President of the Pharmaceutical Research and Development Committee of the China Association of Enterprises with Foreign Investment, based on international experience analysis, said that commercial insurance products in many foreign countries include supplementary insurance and high-end insurance.
-
Going overseas, the thorny and glory of Chinese innovative drugs
Time of Update: 2021-11-14
After nine deaths in the research and development of new drugs, innovative pharmaceutical companies discovered that entering medical insurance after listing is not an "iron rice bowl" that can bundle sales .
-
What is the difference between Novartis's $1.3 billion favor of this cutting-edge protein degradation therapy?
Time of Update: 2021-11-14
Today, Dunad Therapeutics announced that it has reached a research and development cooperation agreement with Novartis to jointly develop a new generation of oral targeted protein degradation therapies .
-
In October, many well-known pharmaceutical companies introduced new drugs. What are their highlights?
Time of Update: 2021-11-14
According to incomplete statistics, in October 2021, at least eight Chinese biopharmaceutical companies have reached agreement on new drug introduction cooperation, including Shanghai Pharmaceuticals, Luoxin Pharmaceutical, Huadong Pharmaceutical, Yehui Pharmaceutical, China Resources Double Crane, Hansen Pharmaceutical, etc.
-
Are those children who receive gene therapy okay after 10 years?
Time of Update: 2021-11-14
More than a decade ago, scientists at the University of California at Los Angeles (UCLA) used the gene therapy they developed to treat 10 children born with rare and fatal immune system diseases .
-
The new crown outbreak was approved less than two years ago!
Time of Update: 2021-11-14
This is the world's first antiviral therapy approved for the treatment of patients with mild to moderate COVID-19, allowing patients to take medicines for treatment at home, adding an important new weapon to the early end of the COVID-19 epidemic .
Retrieved November 4, 2021, from https:// -19-lagevrio-molnupiravir-approved-by-mhra [3] How antiviral pill molnupiravir shot ahead in the COVID drug hunt.
-
In October, these more than 10 new drugs were submitted for listing in China, from Roche, Hengrui Pharmaceuticals, Novartis, etc.
Time of Update: 2021-11-14
This submission is for the marketing application of a new drug for the treatment of recurrent or metastatic cervical cancer Public information shows that the antibody cell line of socazolimab was introduced from Sorrento Therapeutics by Lee's Pharmaceutical Factory .
-
FDA launches drug production reporting portal and releases relevant guidance
Time of Update: 2021-11-14
The US FDA launched a new NextGen portal on October 29 to report production data of pharmaceuticals and biological products under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), and subsequently issued two guidelines Help registrants comply with regulations and reporting requirements .
-
The first-line treatment of vomitinib has reached the clinical end point. Why does the EGFR target endure for a long time?
Time of Update: 2021-11-14
Table 2 Sources of statistical data on price changes of EGFR inhibitors: Yaozhi data, list of medical insurance negotiations over the years, list of centralized procurement Domestic EGFR research and development enthusiasm remains high In an environment where many marketed drugs are scrambling to "suicidal" price cuts, there are still a large number of new varieties that are gradually established for research and development .
-
For the entire year, or $82 billion, in addition to mRNA vaccines, what is Pfizer, which has returned to the world's number one, still laying out?
Time of Update: 2021-11-14
In the financial report, Pfizer raised its full-year sales forecast for Comirnaty's new crown vaccine by 7% to approximately US$36 billion .
Pfizer also announced the latest developments in six key R&D pipeline products including the new crown vaccine, gene therapy pipeline, PDE4 inhibitor, TL1A inhibitor, IFN-β inhibitor and oral COVID-19 drugs .
-
Digital Therapy for Mental Health in the United States: The Inherent Paradox of Accessibility and Scale
Time of Update: 2021-11-14
This forces more and more online psychotherapy companies to hire full-time doctors to ensure the quality of services, but the shortage of psychiatrists and salary problems will Restrict the expansion of this type of model in the medium and long term .
However, the shortage of psychiatrists will restrict the development of mental digital therapy in the long term .
-
Johnson & Johnson, Utimes, and Platinum Pharmaceuticals are all developing. When will the first FcRn-targeted new drug arrive?
Time of Update: 2021-11-14
In addition, another important research direction in this field is to develop drugs to inhibit the binding of endogenous FcRn and IgG, thereby treating autoimmune diseases driven by autoantibody .
Retrieved Sep 27, 2021, from https:// Hebo Pharmaceutical Bartolizumab HBM9161 was administered to the first patient in the Phase III trial of systemic myasthenia gravis.
-
Only one year after its establishment, it has cooperated with Gilead and Baekje, holding more than 300 million US dollars. Why is this cutting-edge cell therapy being sought after?
Time of Update: 2021-11-14
FT516 clinical data (source: Fate official website) Frank Yu, the founder/CEO of Huiqiao Capital, who led this round of Shoreline financing, said that they have been investigating the field of iPSC-derived NK cell therapy for many years, and that this field has made encouraging clinical progress.
-
The Q3 report card of multinational pharmaceutical companies has been announced: Merck’s growth rate is unique, Novartis clamors that China’s sales will double, and Aber Maintenance Miller is gradually losing its color...
Time of Update: 2021-11-14
According to statistics from E-pharmaceutical managers, as of today, ten large multinational pharmaceutical companies including Novartis, Merck, Roche, GSK, BMS, Johnson & Johnson, Sanofi, AbbVie, Eli Lilly and Gilead have released their 2021 Third quarter earnings report .
-
2020 National Science and Technology Award List Released (Medical)
Time of Update: 2021-11-14
On November 3, the 2020 National Science and Technology Awards Conference was grandly held in Beijing.
The 91-year-old New China Aircraft Design Master Academician Gu Songfen and the 86-year-old Internationally Famous Nuclear Energy Scientist Academician Wang Dazhong won the country's highest science and technology award .
